Cargando…
Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach
The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG. Knowledge of these parameters across species could be used to avoid unnecessary in vivo PK studies and to enable early PK predictions and ph...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150614/ https://www.ncbi.nlm.nih.gov/pubmed/29634430 http://dx.doi.org/10.1080/19420862.2018.1462429 |
_version_ | 1783357023089328128 |
---|---|
author | Betts, Alison Keunecke, Anne van Steeg, Tamara J. van der Graaf, Piet H. Avery, Lindsay B. Jones, Hannah Berkhout, Jan |
author_facet | Betts, Alison Keunecke, Anne van Steeg, Tamara J. van der Graaf, Piet H. Avery, Lindsay B. Jones, Hannah Berkhout, Jan |
author_sort | Betts, Alison |
collection | PubMed |
description | The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG. Knowledge of these parameters across species could be used to avoid unnecessary in vivo PK studies and to enable early PK predictions and pharmacokinetic/pharmacodynamic (PK/PD) simulations. In this work, population-pharmacokinetic (popPK) modeling was used to determine a single set of ‘typical’ popPK parameters describing the linear PK of mAbs in human, cynomolgus monkey and transgenic mice expressing the human neonatal Fc receptor (hFcRn Tg32), using a rich dataset of 27 mAbs. Non-linear PK was excluded from the datasets and a 2-compartment model was applied to describe mAb disposition. Typical human popPK estimates compared well with data from comparator mAbs with linear PK in the clinic. Outliers with higher than typical clearance were found to have non-specific interactions in an affinity-capture self-interaction nanoparticle spectroscopy assay, offering a potential tool to screen out these mAbs at an early stage. Translational strategies were investigated for prediction of human linear PK of mAbs, including use of typical human popPK parameters and allometric exponents from cynomolgus monkey and Tg32 mouse. Each method gave good prediction of human PK with parameters predicted within 2-fold. These strategies offer alternative options to the use of cynomolgus monkeys for human PK predictions of linear mAbs, based on in silico methods (typical human popPK parameters) or using a rodent species (Tg32 mouse), and call into question the value of completing extensive in vivo preclinical PK to inform linear mAb PK. |
format | Online Article Text |
id | pubmed-6150614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-61506142018-09-24 Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach Betts, Alison Keunecke, Anne van Steeg, Tamara J. van der Graaf, Piet H. Avery, Lindsay B. Jones, Hannah Berkhout, Jan MAbs Reports The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG. Knowledge of these parameters across species could be used to avoid unnecessary in vivo PK studies and to enable early PK predictions and pharmacokinetic/pharmacodynamic (PK/PD) simulations. In this work, population-pharmacokinetic (popPK) modeling was used to determine a single set of ‘typical’ popPK parameters describing the linear PK of mAbs in human, cynomolgus monkey and transgenic mice expressing the human neonatal Fc receptor (hFcRn Tg32), using a rich dataset of 27 mAbs. Non-linear PK was excluded from the datasets and a 2-compartment model was applied to describe mAb disposition. Typical human popPK estimates compared well with data from comparator mAbs with linear PK in the clinic. Outliers with higher than typical clearance were found to have non-specific interactions in an affinity-capture self-interaction nanoparticle spectroscopy assay, offering a potential tool to screen out these mAbs at an early stage. Translational strategies were investigated for prediction of human linear PK of mAbs, including use of typical human popPK parameters and allometric exponents from cynomolgus monkey and Tg32 mouse. Each method gave good prediction of human PK with parameters predicted within 2-fold. These strategies offer alternative options to the use of cynomolgus monkeys for human PK predictions of linear mAbs, based on in silico methods (typical human popPK parameters) or using a rodent species (Tg32 mouse), and call into question the value of completing extensive in vivo preclinical PK to inform linear mAb PK. Taylor & Francis 2018-05-14 /pmc/articles/PMC6150614/ /pubmed/29634430 http://dx.doi.org/10.1080/19420862.2018.1462429 Text en © 2018 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Reports Betts, Alison Keunecke, Anne van Steeg, Tamara J. van der Graaf, Piet H. Avery, Lindsay B. Jones, Hannah Berkhout, Jan Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title_full | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title_fullStr | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title_full_unstemmed | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title_short | Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach |
title_sort | linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hfcrn tg32 transgenic mouse using a population-modeling approach |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150614/ https://www.ncbi.nlm.nih.gov/pubmed/29634430 http://dx.doi.org/10.1080/19420862.2018.1462429 |
work_keys_str_mv | AT bettsalison linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT keuneckeanne linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT vansteegtamaraj linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT vandergraafpieth linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT averylindsayb linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT joneshannah linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach AT berkhoutjan linearpharmacokineticparametersformonoclonalantibodiesaresimilarwithinaspeciesandacrossdifferentpharmacologicaltargetsacomparisonbetweenhumancynomolgusmonkeyandhfcrntg32transgenicmouseusingapopulationmodelingapproach |